MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · IEX Real-Time Price · USD
21.02
-1.11 (-5.02%)
At close: Mar 24, 2023, 4:00 PM
19.96
-1.06 (-5.04%)
After-hours: Mar 24, 2023, 6:06 PM EDT
-5.02%
Market Cap 823.02M
Revenue (ttm) n/a
Net Income (ttm) -64.51M
Shares Out 39.15M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 210,234
Open 22.13
Previous Close 22.13
Day's Range 20.14 - 22.18
52-Week Range 4.25 - 25.32
Beta 0.93
Analysts Buy
Price Target 22.27 (+5.95%)
Earnings Date Mar 20, 2023

About MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Switzerland
Stock Exchange NASDAQ
Ticker Symbol MLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price forecast is $22.27, which is an increase of 5.95% from the latest price.

Price Target
$22.27
(5.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

4 days ago - GlobeNewsWire

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa

1 month ago - GlobeNewsWire

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody ® sonelokimab in active psoriatic arthritis

3 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeu tics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

4 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics to i nitiate g lobal Phase 2 s tudy of the Nanobody ® s onelokimab in p atients with active psoriatic arthritis

6 months ago - GlobeNewsWire

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

8 months ago - GlobeNewsWire

HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders

HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class agent for multiple inflammatory disorders...

8 months ago - Benzinga

Why MoonLake Immunotherapeutics Shares Are Surging Higher Today

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares are trading approximately 23% higher Tuesday morning on high volume. MoonLake's average session volume over a 100-day period is about 158,900, accordi...

10 months ago - Benzinga

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

11 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Helix Acquisition Corp. with MoonLake Immunotherapeutics AG

New York, New York--(Newsfile Corp. - October 4, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Helix Acquisition Corp. (NASDAQ: HL...

1 year ago - Newsfile Corp

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

ZUG, Switzerland & BOSTON--(BUSINESS WIRE)--MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases and...

1 year ago - Business Wire

Helix Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Boston, Massachusetts--(Newsfile Corp. - October 22, 2020) - Helix Acquisition Corp. (NASDAQ: HLXA) (the "Company") announced today that on Oct. 22, 2020 it closed its initial public offering of 11,50...

2 years ago - Newsfile Corp

Helix Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

Boston, Massachusetts--(Newsfile Corp. - October 19, 2020) - Helix Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 10,000,000 Class A ordinary shares at...

2 years ago - Newsfile Corp